Astrazeneca (AZN) Short-term Investments (2009 - 2026)

Astrazeneca (AZN) has reported Short-term Investments for 18 consecutive years, with $382.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 81.9% year-over-year to $382.0 million; the TTM figure through Mar 2026 stood at $382.0 million (up 81.9% YoY), while the FY2025 annual figure was $498.0 million, up 1245.95% from the prior year.
• Short-term Investments came in at $382.0 million for Q1 2026 at Astrazeneca, down from $498.0 million in the prior quarter.
• The five-year high for Short-term Investments was $509.0 million in Q2 2025, with the low at -$290.0 million in Q3 2022.
• Average Short-term Investments over 5 years is $169.9 million, with a median of $163.0 million recorded in 2023.
• Across the five-year window, Short-term Investments sank 422.22% in 2022 and soared 1245.95% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $87.0 million in 2022, then surged by 33.33% to $116.0 million in 2023, then plunged by 68.1% to $37.0 million in 2024, then jumped by 1245.95% to $498.0 million in 2025, then dropped by 23.29% to $382.0 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $382.0 million, $498.0 million, and $502.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.